Browse PRKAR2B

Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell membrane Note=Colocalizes with PJA2 in the cytoplasm and at the cell membrane.
Domain PF00027 Cyclic nucleotide-binding domain
PF02197 Regulatory subunit of type II PKA R-subunit
Function

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0001933 negative regulation of protein phosphorylation
GO:0003014 renal system process
GO:0003091 renal water homeostasis
GO:0006469 negative regulation of protein kinase activity
GO:0006631 fatty acid metabolic process
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0007611 learning or memory
GO:0007612 learning
GO:0030104 water homeostasis
GO:0032147 activation of protein kinase activity
GO:0033673 negative regulation of kinase activity
GO:0033674 positive regulation of kinase activity
GO:0033762 response to glucagon
GO:0034199 activation of protein kinase A activity
GO:0042326 negative regulation of phosphorylation
GO:0042493 response to drug
GO:0043434 response to peptide hormone
GO:0044708 single-organism behavior
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0045860 positive regulation of protein kinase activity
GO:0048871 multicellular organismal homeostasis
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050890 cognition
GO:0050891 multicellular organismal water homeostasis
GO:0051348 negative regulation of transferase activity
GO:0071375 cellular response to peptide hormone stimulus
GO:0071377 cellular response to glucagon stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0097332 response to antipsychotic drug
GO:0097338 response to clozapine
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:2000479 regulation of cAMP-dependent protein kinase activity
GO:2000480 negative regulation of cAMP-dependent protein kinase activity
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0004862 cAMP-dependent protein kinase inhibitor activity
GO:0008603 cAMP-dependent protein kinase regulator activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0030291 protein serine/threonine kinase inhibitor activity
GO:0030551 cyclic nucleotide binding
GO:0030552 cAMP binding
GO:0031625 ubiquitin protein ligase binding
GO:0034236 protein kinase A catalytic subunit binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0051018 protein kinase A binding
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0005813 centrosome
GO:0005929 cilium
GO:0005952 cAMP-dependent protein kinase complex
GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0043198 dendritic shaft
GO:0044297 cell body
GO:0044309 neuron spine
GO:0044441 ciliary part
GO:0045121 membrane raft
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0097546 ciliary base
GO:0098589 membrane region
GO:0098794 postsynapse
GO:0098857 membrane microdomain
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04910 Insulin signaling pathway
Reactome R-HSA-8854518: AURKA Activation by TPX2
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-445717: Aquaporin-mediated transport
R-HSA-111996: Ca-dependent events
R-HSA-111997: CaM pathway
R-HSA-111933: Calmodulin induced events
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-5617833: Cilium Assembly
R-HSA-1489509: DAG and IP3 signaling
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-180024: DARPP-32 events
R-HSA-186763: Downstream signal transduction
R-HSA-212718: EGFR interacts with phospholipase C-gamma
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-112040: G-protein mediated events
R-HSA-69275: G2/M Transition
R-HSA-163359: Glucagon signaling in metabolic regulation
R-HSA-381676: Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
R-HSA-5610787: Hedgehog 'off' state
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-163685: Integration of energy metabolism
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-1430728: Metabolism
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-111885: Opioid Signalling
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-163615: PKA activation
R-HSA-164378: PKA activation in glucagon signalling
R-HSA-111931: PKA-mediated phosphorylation of CREB
R-HSA-112043: PLC beta mediated events
R-HSA-167021: PLC-gamma1 signalling
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-422356: Regulation of insulin secretion
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-5358351: Signaling by Hedgehog
R-HSA-186797: Signaling by PDGF
R-HSA-166520: Signalling by NGF
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRKAR2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRKAR2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRKAR2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1610.736
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4110.789
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5680.578
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2820.555
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7460.592
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3090.867
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2230.636
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2870.838
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0810.956
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1050.158
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.650.13
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2290.215
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRKAR2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRKAR2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRKAR2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRKAR2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRKAR2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRKAR2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRKAR2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRKAR2B
Nameprotein kinase, cAMP-dependent, regulatory, type II, beta
Aliases RII-BETA; H_RG363E19.2; WUGSC:H_RG363E19.2; cAMP-dependent protein kinase type II-beta regulatory chain; cAM ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRKAR2B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRKAR2B.
ID Name Drug Type Targets #Targets
DB02527Cyclic Adenosine MonophosphateSmall MoleculeHCN2, PRKAR1A, PRKAR2B3